[go: up one dir, main page]

PE20190355A1 - Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo - Google Patents

Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo

Info

Publication number
PE20190355A1
PE20190355A1 PE2018003336A PE2018003336A PE20190355A1 PE 20190355 A1 PE20190355 A1 PE 20190355A1 PE 2018003336 A PE2018003336 A PE 2018003336A PE 2018003336 A PE2018003336 A PE 2018003336A PE 20190355 A1 PE20190355 A1 PE 20190355A1
Authority
PE
Peru
Prior art keywords
cysteine
glutamic acid
peptide
acid
same
Prior art date
Application number
PE2018003336A
Other languages
English (en)
Inventor
Jung Kuk Kim
Young Jin Park
In Young Choi
Sung Youb Jung
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190355(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20190355A1 publication Critical patent/PE20190355A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a un derivado de glucagon o un conjugado que contiene el mismo, y en forma especifica, una composicion farmaceutica, que comprende un peptido que comprende la secuencia de aminoacidos de la siguiente formula general 1: X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X23-X24-W-L-X27-X28-X29-X30 (Formula general 1, SEQ ID NO: 45), en donde X1 es histidina (H), desamino-histidilo, N-dimetil-histidilo, beta-hidroxiimidazopropionilo, 4-imidazoacetilo, entre otros; X2 es acido alfa-metil-glutamico, acido aminoisobutirico (Aib), D-alanina, glicina (G), entre otros; X7 es treonina (T), valina (V), o cisteina (C); X10 es tirosina (Y) o cisteina (C ); X12 es lisina (K) o cisteina (C ); X13 es tirosina (Y) o cisteina (C ); X14 es leucina (L) o cisteina (C ); X15 es acido aspartico (D), acido glutamico (E), o cisteina (C); X16 es acido glutamico (E ) acido aspartico (D), serina (S), acido alfa-metil-glutamico, o cisteina (C), o esta ausente; X17 es acido aspartico (D), glutamina (Q), acido glutamico (E ), entre otros; X18 es alanina (A), acido aspartico (D), acido glutamico (E ), entre otros; X19 es alanina (A), arginina (R ), entre otros; X20 es lisina (K), histidina (H), entre otros; X21 es acido aspartico (D), acido glutamico (E ); entre otros; X23 es isoleucina (I), valina (V), entre otros; X24 es valina (V), arginina (R ), entre otros, X27 es isoleucina (I), valina (V), entre otros; X28 es glutamina (Q), lisina (K); X29 es lisina (K), alanina ( A); X30 es cisteina (C); entre otros; donde el extremo C-terminal del peptido esta amidado, no modificado y el peptido es un derivado del glucagon nativo capaz de activar un receptor de glucagon, el cual comprende una secuencia de aminoacidos que consiste en las SEQ ID NOS: 2 a 44. Tambien se refiere a un conjugado aislado que comprende un resto peptidico y un resto de material biocompatible que se liga al resto del peptido. Dicha composicion farmaceutica es util para prevenir o tratar hipoglucemia, sindrome metabolico e hiperinsulinismo congenito.
PE2018003336A 2016-06-29 2017-06-29 Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo PE20190355A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160081995 2016-06-29
KR20160182982 2016-12-29
KR20170069217 2017-06-02

Publications (1)

Publication Number Publication Date
PE20190355A1 true PE20190355A1 (es) 2019-03-07

Family

ID=60787387

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003336A PE20190355A1 (es) 2016-06-29 2017-06-29 Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo

Country Status (23)

Country Link
US (1) US11142559B2 (es)
EP (1) EP3479841A4 (es)
JP (2) JP7208020B2 (es)
KR (2) KR102005457B1 (es)
CN (1) CN109641035A (es)
AU (1) AU2017289014B2 (es)
BR (1) BR112018077457A2 (es)
CA (1) CA3029518A1 (es)
CL (1) CL2018003754A1 (es)
CO (1) CO2019003182A2 (es)
DO (1) DOP2018000297A (es)
EC (1) ECSP19021223A (es)
IL (1) IL263934B2 (es)
MX (1) MX2019000019A (es)
MY (1) MY190855A (es)
PE (1) PE20190355A1 (es)
PH (1) PH12018502742A1 (es)
SG (1) SG11201811697SA (es)
TN (1) TN2018000452A1 (es)
TW (1) TWI757305B (es)
UA (1) UA126662C2 (es)
WO (1) WO2018004283A2 (es)
ZA (1) ZA201900470B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
ES2897935T3 (es) * 2014-03-31 2022-03-03 Hanmi Pharm Ind Co Ltd Método para mejorar la solubilidad de proteína y péptido mediante el uso del enlace a un fragmento Fc de inmunoglobulina
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
PE20191236A1 (es) 2016-12-29 2019-09-11 Hoffmann La Roche Compuestos de pirazolopirimidina y metodos de uso de los mismos
WO2018143729A1 (ko) * 2017-02-03 2018-08-09 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
BR112021006477A2 (pt) * 2018-10-04 2021-07-13 Hanmi Pharm. Co., Ltd. combinação que compreende uma substância com atividade para um receptor de glucagon ou um conjugado do mesmo, kit e composição farmacêutica para prevenir ou tratar doenças
EP3900734A4 (en) * 2018-12-21 2022-10-12 Hanmi Pharm. Co., Ltd. Pharmaceutical composition containing insulin and glucagon
CN110551203B (zh) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 一种艾塞那肽类似物
EP4043026A4 (en) * 2019-10-04 2024-01-10 Hanmi Pharm. Co., Ltd. Glucagon, composition comprising glp-1 receptor and gip receptor dual agonist and therapeutic use thereof
CN110845601B (zh) * 2019-10-12 2021-01-19 广东药科大学 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
WO2021201654A1 (ko) * 2020-04-03 2021-10-07 한미약품 주식회사 Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물
TW202203963A (zh) * 2020-04-20 2022-02-01 南韓商韓美藥品股份有限公司 用於預防或治療高血脂症之包含三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑或其接合物之組成物及其使用方法
IL297266A (en) * 2020-04-29 2022-12-01 Onegene Biotechnology Inc Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes
EP4154867A4 (en) * 2020-05-22 2025-01-29 Hanmi Pharm. Co., Ltd. LIQUID FORMULATION
MX2022014669A (es) * 2020-05-22 2023-02-13 Hanmi Pharm Ind Co Ltd Formulacion liquida de conjugado de derivado de glucagon de accion prolongada.
WO2022013306A1 (en) 2020-07-14 2022-01-20 Universität Heidelberg Oral pharmaceutical compositions comprising lipid conjugates
IL299778A (en) * 2020-07-15 2023-03-01 Hanmi Pharm Ind Co Ltd Therapeutic use of glucagon derivative or conjugate thereof for liver disease
WO2022216129A1 (ko) 2021-04-09 2022-10-13 한미약품 주식회사 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE19618812C1 (de) 1996-05-10 1997-11-20 Karlsruhe Forschzent Sensor zum Nachweis von Proteinen und Verfahren zu dessen Herstellung
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
CA2455963C (en) 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
EA009366B1 (ru) 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR100775343B1 (ko) 2003-11-13 2007-11-08 한미약품 주식회사 면역글로불린 Ｆｃ 영역을 캐리어로 포함하는 약제학적조성물
ES2495741T3 (es) 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8669228B2 (en) 2007-01-05 2014-03-11 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP5385266B2 (ja) * 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2008155900A1 (ja) 2007-06-19 2008-12-24 Otsuka Chemical Co., Ltd. 糖鎖付加glp-1ペプチド
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CL2009001424A1 (es) * 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
AU2009260301B2 (en) 2008-06-17 2015-09-03 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
JP6108659B2 (ja) * 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AU2011206979B2 (en) 2010-01-20 2015-09-10 Zealand Pharma A/S Treatment of cardiac conditions
KR20130018410A (ko) * 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
KR20130132931A (ko) 2010-12-22 2013-12-05 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체 활성을 나타내는 글루카곤 유사체들
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
KR102497726B1 (ko) * 2011-05-18 2023-02-07 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
UA126465C2 (uk) * 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
KR101577734B1 (ko) * 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
EP2729493B1 (en) * 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
JP6324315B2 (ja) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
US20150005233A1 (en) * 2012-02-08 2015-01-01 Seneb Biosciences, Inc. Treatment of hypoglycemia
US9745359B2 (en) 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
TR201808818T4 (tr) 2012-06-21 2018-07-23 Novo Nordisk As Gip reseptör aktivitesi sergileyen glukagon analogları.
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
TWI652071B (zh) * 2012-11-06 2019-03-01 韓美藥品股份有限公司 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
BR112015011478B1 (pt) * 2012-11-20 2022-10-25 Mederis Diabetes, Llc Produtos de peptídeo, seus usos e composição farmacêutica
DK2922877T3 (da) * 2012-11-20 2019-01-02 Eumederis Pharmaceuticals Inc Forbedrede peptidlægemidler
MA38276B1 (fr) 2012-12-21 2018-03-30 Sanofi Sa Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
HK1226084A1 (zh) 2013-08-16 2017-09-22 Medimmune Limited 用於治疗糖尿病的gip和glp-1受体双重激动剂
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
TWI802396B (zh) * 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
EP3575314B1 (en) * 2014-12-30 2024-02-14 Hanmi Pharm. Co., Ltd. Glucagon derivative
WO2017003191A1 (en) * 2015-06-30 2017-01-05 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201718629A (zh) 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
CN109069569B (zh) 2015-12-02 2023-02-14 韩美药品株式会社 使用脂肪酸衍生物的蛋白缀合物及其制备方法
CR20180380A (es) 2015-12-31 2018-12-07 Hanmi Pharm Ind Co Ltd Agosnista triple de receptores de glucagón/glp-1/gip

Also Published As

Publication number Publication date
CN109641035A (zh) 2019-04-16
NZ750267A (en) 2023-12-22
US20190119347A1 (en) 2019-04-25
MX2019000019A (es) 2019-05-06
CL2018003754A1 (es) 2019-02-08
BR112018077457A2 (pt) 2019-04-02
CA3029518A1 (en) 2018-01-04
AU2017289014A1 (en) 2019-02-14
KR20190092344A (ko) 2019-08-07
JP7399212B2 (ja) 2023-12-15
EP3479841A4 (en) 2020-03-04
JP2019524675A (ja) 2019-09-05
JP2022107595A (ja) 2022-07-22
UA126662C2 (uk) 2023-01-11
IL263934A (en) 2019-02-03
CO2019003182A2 (es) 2019-06-11
PH12018502742A1 (en) 2019-04-15
KR102005457B1 (ko) 2019-07-30
WO2018004283A2 (ko) 2018-01-04
WO2018004283A3 (ko) 2018-02-22
JP7208020B2 (ja) 2023-01-18
KR20180002544A (ko) 2018-01-08
KR102395856B1 (ko) 2022-05-10
IL263934B2 (en) 2023-10-01
ZA201900470B (en) 2020-07-29
TN2018000452A1 (en) 2020-06-15
TW201803894A (zh) 2018-02-01
TWI757305B (zh) 2022-03-11
US11142559B2 (en) 2021-10-12
MY190855A (en) 2022-05-12
SG11201811697SA (en) 2019-01-30
IL263934B1 (en) 2023-06-01
AU2017289014B2 (en) 2019-12-05
ECSP19021223A (es) 2019-04-30
EP3479841A2 (en) 2019-05-08
DOP2018000297A (es) 2019-03-15

Similar Documents

Publication Publication Date Title
PE20190355A1 (es) Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
PE20140765A1 (es) Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
AR086969A1 (es) Conjugado que comprende oxontomodulina y un fragmento de inmunoglobulina, y su uso
PE20171154A1 (es) Derivados de glucagon con estabilidad mejorada
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
JP2018510622A5 (es)
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
PE20211300A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
JP2018504419A5 (es)
PE20171442A1 (es) Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores
PE20120563A1 (es) Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
NZ768446A (en) Novel glp-1 analogues
JP2018504901A5 (es)
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
AR105616A1 (es) Proteínas de fusión
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
RU2020117156A (ru) Конъюгаты анти-cd40 антитела и лекарственного средства
PE20090711A1 (es) Region constante de anticuerpo mutante
RU2015101697A (ru) Аналоги глюкагона, обладающие активностью рецептора gip
EA201291234A1 (ru) Аналоги глюкагона
PE20140724A1 (es) Coagonistas del receptor de glucagon/glp-1
IL276170B1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
JP2016510728A5 (es)